Lactobacillus Mucosae Composition for Gut Microbiota Evaluation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of an effective evaluation system for selecting food compositions that increase the diversity of gut bacteria and short-chain fatty acids in the human gut microbiota, particularly for Japanese individuals, as existing models do not account for the unique composition of gut bacteria in Japanese populations and are limited by the use of human feces, which varies among individuals.
Innovation Solution
A novel gut microbiota model is constructed using dominant gut bacteria from Japanese populations, cultured with indigestible dietary fibers to standardize the microbiota and evaluate the effectiveness of food compositions, and Lactobacillus mucosae is identified for its ability to increase short-chain fatty acids and diversity, with a method to culture these bacteria in a modified GAM bouillon medium under anaerobic conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a novel gut microbiota model is constructed using dominant gut bacteria from Japanese populations, then the evaluation precision for food compositions is improved, but the device complexity increases
Solution Approach 1:
The gut microbiota model is segmented into specific dominant bacterial species from Japanese populations (Bifidobacterium, Blautia, Collinsella, Streptococcus, and other Firmicutes), allowing precise evaluation of food compositions against defined microbial communities rather than using heterogeneous human fecal samples
Solution Approach 2:
A simplified in vitro model copying the essential features of Japanese gut microbiota is created using cultured bacterial species, enabling standardized evaluation without requiring complex human subject studies while maintaining biological relevance
2Reliability
If Lactobacillus mucosae is used as an active ingredient, then the gut microbiota improving function is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The invention specifies precise parameters for Lactobacillus mucosae culture including pH range (6.0-7.5), temperature (30-37°C), and culture time (12-24 hours) to ensure consistent production of the gut microbiota improving function while maintaining manufacturing feasibility
Solution Approach 2:
Lactobacillus mucosae exhibits self-regulating properties in the gut environment, naturally adapting to intestinal conditions and exerting its probiotic effects without requiring extremely precise manufacturing control, as the bacteria's physiological responses are inherently robust to moderate variations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The model allows for the evaluation of food compositions that enhance gut microbiota diversity and short-chain fatty acid production without using human samples, and Lactobacillus mucosae is shown to promote bifidobacteria proliferation, offering a new probiotic solution for improving gut health.
Implementation Method 1
Lactobacillus mucosae has a function of improving the gut microbiota, that is, a function of increasing the short-chain fatty acids
Implementation Method 2
Lactobacillus mucosae is shown to promote bifidobacteria proliferation
Data Source
AI summary
An object of one present invention is to provide a food composition including, as an active ingredient thereof, Lactobacillus mucosae that has a function of improving a gut microbiota. An object of another present invention is to provide an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof. The one present invention provides a composition for improving the gut microbiota, including the bacterial cell or a culture of Lactobacillus mucosae as an active ingredient thereof. The other present invention provides an increasing drug for the rate of bifidobacteria in the human intestine and a bifidobacteria proliferation promoting drug, including Lactobacillus mucosae as an active ingredient thereof.